Trial Profile
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Blarcamesine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Anavex Life Sciences
- 19 Dec 2023 According to an Anavex Life Sciences media release, data from the blarcamesine in Alzheimers disease Phase 2b/3 randomized, placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal.
- 19 Dec 2023 According to an Anavex Life Sciences media release, the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer's disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agencys centralised procedure.
- 20 Nov 2023 According to an Anavex Life Sciences media release, the company has initiated the process for submitting a Marketing Authorisation application to the EMA with the submission of the Centralised Procedure request with the goal of the Authorisation allowing direct access to the market of the European Union for oral blarcamesine for the treatment of Alzheimer's disease.